| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Tom A. Elasy | Q91233139 |
| P2093 | author name string | John M Stafford | |
| P2860 | cites work | Metformin: An Update | Q22241145 |
| Mechanism by which metformin reduces glucose production in type 2 diabetes | Q22241286 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Metformin | Q22250907 | ||
| Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase | Q28296225 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? | Q29618125 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study | Q45074002 | ||
| Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes | Q45124446 | ||
| A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors | Q45124693 | ||
| Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes | Q46486537 | ||
| A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome | Q46546161 | ||
| Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus | Q46795016 | ||
| Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes | Q46800406 | ||
| Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes | Q46817499 | ||
| Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome | Q46853322 | ||
| Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study | Q46861155 | ||
| Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes | Q46966704 | ||
| Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients | Q46966714 | ||
| Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology | Q47446497 | ||
| Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. | Q51551544 | ||
| Rosiglitazone does not alter the pharmacokinetics of metformin. | Q51552735 | ||
| Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. | Q51558893 | ||
| Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. | Q51571115 | ||
| Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? | Q51615482 | ||
| Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. | Q51616426 | ||
| Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. | Q51620602 | ||
| The natural history of impaired glucose tolerance in the Pima Indians. | Q51623599 | ||
| Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. | Q54383566 | ||
| Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. | Q54656315 | ||
| NIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activity | Q71441633 | ||
| Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production | Q72020678 | ||
| Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance | Q73685475 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Therapy of NAFLD: insulin sensitizing agents | Q30439790 | ||
| Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | Q31976463 | ||
| Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial | Q33434303 | ||
| Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin | Q33863260 | ||
| Roles of PPARs in health and disease. | Q33934899 | ||
| Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes | Q33957444 | ||
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
| Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone | Q34324049 | ||
| Thiazolidinediones | Q34346862 | ||
| Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine | Q34398058 | ||
| Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
| Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia | Q34474718 | ||
| Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother | Q34518606 | ||
| The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. | Q34522920 | ||
| Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus | Q34541876 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study | Q35606593 | ||
| Pathogenesis of type 2 diabetes mellitus | Q35861736 | ||
| Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships | Q35883220 | ||
| The effects of glucose and insulin on renal electrolyte transport | Q35902340 | ||
| Molecular physiology and genetics of NIDDM. Importance of metabolic staging | Q35981574 | ||
| New targets for PPARgamma in the vessel wall: implications for restenosis | Q36042269 | ||
| Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation | Q36144467 | ||
| Induction of leptin resistance through direct interaction of C-reactive protein with leptin | Q38314557 | ||
| Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance | Q40964485 | ||
| Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. | Q42472146 | ||
| Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway | Q42477113 | ||
| Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial | Q42685341 | ||
| Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes | Q43982800 | ||
| Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients | Q44018167 | ||
| Coronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring study | Q44081087 | ||
| Metabolic effects of visceral fat accumulation in type 2 diabetes | Q44204024 | ||
| Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver | Q44225982 | ||
| Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes | Q44453179 | ||
| Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial | Q44768165 | ||
| Plasma adiponectin levels and risk of myocardial infarction in men. | Q44843420 | ||
| Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes | Q44909522 | ||
| Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin | Q44962639 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| amidines | Q423088 | ||
| anti-diabetic medication | Q575062 | ||
| thiazoles | Q2420555 | ||
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 503-510 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Vascular Health and Risk Management | Q7916443 |
| P1476 | title | Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes | |
| P478 | volume | 3 |
| Q37176719 | Beneficial effects of combined resveratrol and metformin therapy in treating diet-induced insulin resistance |
| Q64084960 | Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics |
| Q34161200 | Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis |
| Q36117595 | Diabetes mellitus: new challenges and innovative therapies |
| Q37188432 | Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study |
| Q41864380 | Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice |
Search more.